Picture of Nyxoah SA logo

NYXH — Nyxoah SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Belgium's Nyxoah Q4 net revenue jumps 347% on US launch

Overview

Belgium medical device maker's Q4 net revenue grew 347% yr/yr, driven by first quarter of U.S. commercialization

Company reported Q4 gross margin of circa 64%

Outlook

Nyxoah expects U.S. net revenue to grow by about 25% in Q1 2026 sequentially

Company expects Q2 2026 U.S. net revenue to grow by about 25% over Q1 2026

International revenue expected to follow typical seasonal pattern

Result Drivers

U.S. COMMERCIAL LAUNCH - Q4 revenue surge driven by first full quarter of Genio system sales in U.S. after FDA approval

REIMBURSEMENT SUPPORT - Consistent reimbursement by major commercial payors and Medicare supported U.S. sales momentum

Company press release: ID:nGNE3dl8ds

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 EPS-EUR 0.59
Q4 Gross Margin64.00%
Q4 Basic EPS-EUR 0.59
Q4 Gross ProfitEUR 3.63 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell" The average consensus recommendation for the advanced medical equipment & technology peer group is "buy" Wall Street's median 12-month price target for Nyxoah SA is €10.10, about 280.4% above its March 19 closing price of €2.66 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Nyxoah SA

See all news